Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024

Crinetics Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.93 revenue$640,000

Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.
Cash, equivalents, and investments total $901.0M as of March 31, 2024, partly from $350M private placement in Feb.
Paltusotine PATHFNDR-2 Phase 3 met primary and all secondary endpoints; NDA submission expected in 2H 2024.
Initial atumelnant Phase 2 results in CAH and Cushing's to be presented at ENDO 2024 (June 1-4).
Plan to initiate paltusotine Phase 3 in carcinoid syndrome by end of 2024 pending FDA discussions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.

Period: the first quarter ended March 31, 2024
Revenue: $0.6 million
Net income: $66.9 million
Result: reported results

Exact text from the filing

of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.